K Pharma

K Pharma EBITDA per Share

The EBITDA per Share of K Pharma (4896.T) as of Oct 23, 2026 is -78.93 JPY. In the previous year, EBITDA per Share was -72.07 JPY — a change of 9.52% (lower).

EBITDA per Share

-78.93JPY

YoY

9.52%

Last updated:

EBITDA per Share of K Pharma is 2025 -78.93 JPY. EBITDA per Share of K Pharma was 2024 -72.07 JPY. It decreases by 9.52% lower compared to the previous year.

The K Pharma EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2021
-18.85 JPY
Jan 1, 2022
-30.44 JPY
Jan 1, 2023
39.23 JPY
Jan 1, 2024
-72.07 JPY
Jan 1, 2025
-78.93 JPY
The K Pharma EBITDA per Share history
YEAREBITDA per ShareYoY
-78.93JPY+9.52%
-72.07JPY-283.71%
39.23JPY-228.89%
-30.44JPY+61.52%
-18.85JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

K Pharma Stock analysis

What does K Pharma do? K Pharma Inc generates revenue through the research, development, manufacture, and sale of pharmaceuticals within a single segment. The company focuses on induced pluripotent stem cell (iPS) drug discovery, creating neural progenitor cells from iPS cells for spinal cord injury treatments. These cells are cryopreserved and transplanted in 200,000-cell injections. Additionally, K Pharma Inc develops regenerative medicine products, targeting medical applications for nerve-related conditions. The firm's primary customers are healthcare providers and medical institutions requiring advanced treatments for spinal cord injuries and regenerative therapies. The company's core products include iPS-derived neural progenitor cell therapies and regenerative medicine solutions. These are sold to hospitals and clinics specializing in neurology and regenerative medicine. K Pharma Inc's business model centers on leveraging iPS cell technology to create innovative treatments, with revenue derived from the sale of these specialized pharmaceutical and regenerative medicine products. The firm's single-segment operations ensure focused development and commercialization of its iPS-based therapies. K Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about K Pharma stock

EBITDA per Share of K Pharma is -78.93 JPY in 2025.

EBITDA per Share of K Pharma changed from -72.07 JPY to -78.93 JPY, representing a 9.52% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share K Pharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — K Pharma

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — K Pharma